Hemostatic gelatin sponge is a superior matrix to matrigel for establishment of LNCaP human prostate cancer in nude mice

Prostate

Volumn 72, Issue 15, 2012, Pages 1669-1677

  Cui, Lingling ^a,b   Chen, Pingping ^a,c   Tan, Zongqing ^a   Li, Wenjie ^b   Dong, Zhongyun ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

animal model; hemostatic gelatin sponge; Matrigel; prostate cancer; VETSPON

Indexed keywords

CASPASE 3; GELATIN SPONGE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIGEL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INCIDENCE; CARCINOGENESIS; CELL GROWTH; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HEMOSTASIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN; DRUG COMBINATIONS; GELATIN SPONGE, ABSORBABLE; GENE EXPRESSION; HEMOSTATICS; HUMANS; LAMININ; MALE; MICE; MICE, NUDE; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTEOGLYCANS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867075694     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22520     Document Type: Article

References (35)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61 (4): 212-236.
2. Crawford ED,. Challenges in the management of prostate cancer. Br J Urol 1992; 70 (Suppl 1): 33-38.
3. Gulley J, Figg WD, Dahut WL,. Treatment options for androgen-independent prostate cancer. Clin Adv Hematol Oncol 2003; 1 (1): 49-57.
4. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA,. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980; 37: 115-132.
5. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP,. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43 (4): 1809-1818.
6. Kleinman HK, Martin GR,. Matrigel: Basement membrane matrix with biological activity. Semin Cancer Biol 2005; 15 (5): 378-386.
7. Kleinman HK, McGarvey ML, Liotta LA, Robey PG, Tryggvason K, Martin GR,. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochem 1982; 21 (24): 6188-6193.
8. Fan L, Pepicelli CV, Dibble CC, Catbagan W, Zarycki JL, Laciak R, Gipp J, Shaw A, Lamm ML, Munoz A, Lipinski R, Thrasher JB, Bushman W,. Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 2004; 145 (8): 3961-3970.
9. Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, Bartsch G, Klocker H,. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 2002; 9 (2): 117-125.
10. Zheng X, Cui XX, Gao Z, Zhao Y, Lin Y, Shih WJ, Huang MT, Liu Y, Rabson A, Reddy B, Yang CS, Conney AH,. Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila) 2010; 3 (1): 114-124.
11. Kumar P, Benedict R, Urzua F, Fischbach C, Mooney D, Polverini P,. Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Invest 2005; 85 (6): 756-767.
12. Jenkins HP, Senz EH, Owen HW, Jampolis RW,. Present status of gelatin sponge for the control of hemorrhage; with experimental data on its use for wounds of the great vessels and the heart. J Am Med Assoc 1946; 132 (11): 614-619.
13. Barnes AC,. The use of gelatin foam sponges in obstetrics and gynecology. Am J Obstet Gynecol 1947; 54 (1): 105-107.
14. Rarig HR,. Successful use of gelatin foam sponge in surgical restoration of fertility. Am J Obstet Gynecol 1963; 86: 136.
15. Charlesworth TM, Agthe P, Moores A, Anderson DM,. The use of haemostatic gelatin sponges in veterinary surgery. J Small Anim Pract 2012; 53 (1): 51-556.
16. Rohanizadeh R, Swain MV, Mason RS,. Gelatin sponges (Gelfoam) as a scaffold for osteoblasts. J Mater Sci Mater Med 2008; 19 (3): 1173-1182.
17. Chung LW, Li W, Gleave ME, Hsieh JT, Wu HC, Sikes RA, Zhau HE, Bandyk MG, Logothetis CJ, Rubin JS, von Eschenbach AC,. Human prostate cancer model: Roles of growth factors and extracellular matrices. J Cell Biochem Suppl 1992; 16H: 99-105.
18. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW,. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51 (14): 3753-3761.
19. Gleave ME, Hsieh JT, von Eschenbach AC, Chung LW,. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: Implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 1992; 147 (4): 1151-1159.
20. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS,. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57 (3): 205-225.
21. Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH, Revelo M, Lu S,. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 2006; 20 (10): 2315-2325.
22. Olson MV, Lee J, Zhang F, Wang A, Dong Z,. Inducible nitric oxide synthase activity is essential for inhibition of prostatic tumor growth by interferon-beta gene therapy. Cancer Gene Ther 2006; 13 (7): 676-685.
23. Lu S, Dong Z,. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells. Prostate 2006; 66 (9): 996-1004.
24. Muller PY, Janovjak H, Miserez AR, Dobbie Z,. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002; 32 (6): 1372-1374, 1376, 1378-1379.
25. Zhang F, Lee J, Lu S, Pettaway CA, Dong Z,. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 2005; 11 (12): 4512-4520.
26. Zhang F, Lu W, Dong Z,. Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice. Clin Cancer Res 2002; 8 (9): 2942-2951.
27. Ninios YP, Sekeri-Pataryas KE, Sourlingas TG,. Histone H1 subtype preferences of DFF40 and possible nuclear localization of DFF40/45 in normal and trichostatin A-treated NB4 leukemic cells. Apoptosis 2010; 15 (2): 128-138.
28. Neimanis S, Albig W, Doenecke D, Kahle J,. Sequence elements in both subunits of the DNA fragmentation factor are essential for its nuclear transport. J Biol Chem 2007; 282 (49): 35821-35830.
29. Widlak P, Lanuszewska J, Cary RB, Garrard WT,. Subunit structures and stoichiometries of human DNA fragmentation factor proteins before and after induction of apoptosis. J Biol Chem 2003; 278 (29): 26915-26922.
30. Wilson MJ, Sinha AA,. Human prostate tumor angiogenesis in nude mice: Metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells. Anat Rec 1997; 249 (1): 63-73.
31. Yang SH, Hsu CK, Wang KC, Hou SM, Lin FH,. Tricalcium phosphate and glutaraldehyde crosslinked gelatin incorporating bone morphogenetic protein-A viable scaffold for bone tissue engineering. J Biomed Mater Res B Appl Biomater 2005; 74 (1): 468-475.
32. Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, Del Bufalo D,. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 2002; 16 (11): 1453-1455.
33. Biroccio A, Candiloro A, Mottolese M, Sapora O, Albini A, Zupi G, Del Bufalo D,. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J 2000; 14 (5): 652-660.
34. Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, Del Bufalo D,. Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS ONE 2010; 5 (7): e11772.
35. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE,. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005; 24 (19): 3110-3120.